CASI Pharmaceuticals, Inc. Ordinary Shares (CASI) is a publicly traded Healthcare sector company. As of May 21, 2026, CASI trades at $0.21 with a market cap of $4.26M and a P/E ratio of -0.78. CASI moved -38.97% today. Year to date, CASI is -89.88%; over the trailing twelve months it is -91.09%. Its 52-week range spans $0.21 to $7.50. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces CASI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CASI Pharmaceuticals Soars 24.5% After Nasdaq Delisting, Targets OTC Trading: CASI Pharmaceuticals’ shares jumped 24.48% after hours to $0.25 following its decision to transition trading to OTC Markets Group after a formal Nasdaq delisting determination. The company will not appeal the delisting, expects ongoing OTC quotation, and reports market cap of $4.26 million with a 91% year decline.
| Metric | Value |
|---|---|
| Price | $0.21 |
| Market Cap | $4.26M |
| P/E Ratio | -0.78 |
| EPS | $-0.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.50 |
| 52-Week Low | $0.21 |
| Volume | 9.96M |
| Avg Volume | 0 |
| Revenue (TTM) | $30.17M |
| Net Income | $-35.84M |
| Gross Margin | 58.38% |
6 analysts cover CASI: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.